View Older Stories View More Recent Stories

May 9, 2023 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
Apr 18, 2023 07:00AM ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Apr 12, 2023 07:08AM ESSA Pharma Inc. (EPIX) Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
Apr 12, 2023 07:00AM ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
Mar 9, 2023 07:30AM Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Mar 8, 2023 07:00AM ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 13, 2023 05:00PM ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
Feb 7, 2023 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
Feb 2, 2023 04:01PM ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
Dec 13, 2022 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
Nov 17, 2022 04:16PM Summit Therapeutics (SMMT) Appoints Alessandra Cesano to its Board
Nov 10, 2022 07:00AM ESSA Pharma to Participate in Two Upcoming Investor Conferences
Oct 31, 2022 07:02AM ESSA Pharma (EPIX) Suspends Enrollment in Phase 1 Study of EPI-7386
Oct 31, 2022 07:00AM ESSA Provides an Update on its Clinical Collaboration with Janssen
Oct 26, 2022 04:02PM ESSA Pharma (EPIX) Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader
Oct 26, 2022 04:01PM ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
Oct 26, 2022 07:02AM ESSA Pharma Inc. (EPIX) Reports Strong Updated EPI-7386 Phase 1/2 Results
Oct 26, 2022 07:00AM Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Sep 13, 2022 07:05AM ESSA Pharma Inc. (EPIX) Appoints Philip Kantoff to its Board
Sep 13, 2022 07:00AM ESSA Pharma Appoints Philip Kantoff to its Board of Directors
Aug 4, 2022 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022
Jun 27, 2022 04:01PM ESSA Pharma Inc. (EPIX) Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
Jun 27, 2022 04:01PM ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
Jun 2, 2022 07:00AM ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
May 10, 2022 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022
Apr 26, 2022 04:30PM ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Apr 8, 2022 01:00PM ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders
Mar 10, 2022 04:05PM ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
Mar 9, 2022 11:34PM ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Mar 8, 2022 04:30PM ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Feb 3, 2022 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021
Jan 19, 2022 07:00AM ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Nov 18, 2021 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021
Nov 8, 2021 07:00AM ESSA Pharma to Participate in Three Upcoming Investor Conferences
Oct 28, 2021 04:05PM ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat
Oct 7, 2021 09:00AM ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386
Oct 7, 2021 06:32AM ESSA Pharma Inc. (EPIX) and Caris Life Sciences Collaborate for Liquid Biopsy Profiling
Oct 7, 2021 06:30AM Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
Aug 31, 2021 04:05PM ESSA Pharma to Present at Upcoming September Investor Conferences
Aug 16, 2021 07:00AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021
May 25, 2021 07:00AM ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference
May 6, 2021 07:01AM ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
Apr 28, 2021 07:18AM ESSA Pharma (EPIX) Announces Pact with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Apr 28, 2021 07:00AM ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Apr 14, 2021 07:00AM ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
Apr 10, 2021 08:30AM ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting
Mar 26, 2021 04:06PM ESSA Pharma Inc. (EPIX) Announces Change to its Board of Directors
Mar 26, 2021 04:05PM ESSA Announces Change to its Board of Directors
Feb 25, 2021 06:33PM ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 25, 2021 04:30PM ESSA Pharma to Present at Upcoming March Investor Conferences
View More Recent Stories View Older Stories